Valuation: Poxel

Market Cap 12.57M 14.35M 11.67M 10.73M 20.21M 1.38B 20.51M 139M 54.42M 678M 53.87M 52.7M 2.34B P/E 2023
-0.52x
P/E 2024 -0.36x
Enterprise Value 79.65M 90.91M 73.95M 67.95M 128M 8.77B 130M 881M 345M 4.29B 341M 334M 14.83B EV / Sales 2023
33.3x
EV / Sales 2024 11.2x
Free-Float
94.27%
Yield 2023 *
-
Yield 2024 -
1 day+0.50%
1 week-0.70%
Current month-1.92%
1 month-4.04%
3 months-26.21%
6 months-15.96%
Current year-14.70%
1 week 0.2
Extreme 0.195
0.2
1 month 0.19
Extreme 0.1942
0.21
Current year 0.19
Extreme 0.1942
0.48
1 year 0.19
Extreme 0.1942
0.61
3 years 0.12
Extreme 0.115
0.95
5 years 0.12
Extreme 0.115
6.84
10 years 0.12
Extreme 0.115
13.8
Manager TitleAgeSince
Chief Executive Officer 59 10/06/2026
Director of Finance/CFO - 01/12/2022
Corporate Officer/Principal - 01/05/2023
Director TitleAgeSince
Chairman - 31/07/2025
Director/Board Member - 31/07/2025
Director/Board Member - 31/07/2025
Date Insider Type Main position Quantity % Market Cap.
04/02/22 Fiscal year

Founder

67,000 0.2334%
04/02/22 Fiscal year

Founder

6,666 0.0232%
30/01/21 Free

Founder

25,263 0.0888%
Change 5-day change 1-year change 3-year change Capi.($)
+0.50%-0.70%-65.82%-68.67% 12.17M
-0.43%-1.26%+52.13%+85.69% 55.57B
-0.24%-0.37%+57.02%+54.21% 54.26B
-0.54%-0.17%-17.60%-14.20% 23.35B
-1.82%-2.89%+3.61%+421.21% 23.54B
+0.05%+1.68%+38.71%-4.57% 20.32B
+3.16%+2.74%+37.33%-31.36% 17.36B
+1.08%+3.77%+36.92%+593.96% 15.59B
+0.43%-1.67%+166.53%+299.61% 14.96B
-2.03%-1.03%+23.63%+176.42% 14.11B
Average +0.02%-0.32%+33.25%+151.23% 23.91B
Weighted average by Cap. -0.18%-0.23%+43.91%+137.54%

Financials

2023 2024
Net sales 1.98M 2.26M 1.84M 1.69M 3.18M 218M 3.23M 21.91M 8.57M 107M 8.49M 8.3M 369M 6.64M 7.57M 6.16M 5.66M 10.67M 731M 10.82M 73.39M 28.72M 358M 28.43M 27.82M 1.24B
Net income -35.09M -40.05M -32.58M -29.93M -56.41M -3.86B -57.24M -388M -152M -1.89B -150M -147M -6.53B -18.3M -20.89M -16.99M -15.62M -29.42M -2.02B -29.86M -202M -79.23M -986M -78.42M -76.73M -3.41B
Net Debt 46.42M 52.98M 43.1M 39.6M 74.62M 5.11B 75.72M 513M 201M 2.5B 199M 195M 8.64B 67.08M 76.56M 62.28M 57.23M 108M 7.39B 109M 742M 290M 3.61B 287M 281M 12.49B
Logo Poxel
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan.
Employees
5
Date Price Change Volume
22/07/26 0.1996 +0.50% 41,598
21/07/26 €0.1986 -0.30% 198,738
20/07/26 €0.1992 -0.20% 88,732
17/07/26 €0.1996 -0.20% 35,859
16/07/26 €0.2000 0.00% 14,856
  1. Stock Market
  2. Stocks
  3. POXEL Stock